Abstract
Cardiovascular Disease (CVD) is one of the most important causes of morbidity and mortality, and associated with an important economic burden globally. Over the last decade, the prevalence of CVD has been rising globally, and is now associated with millions of death annually in both developed and developing countries. There is good evidence that the immune system is involved in the pathophysiology of CVD. Toll-like receptors (TLRs) and their down-stream signaling pathways play an important role in the immune system. Recent studies have suggested that the TLRs are involved in atherogenesis, including stroke, myocardial infarction, ischemiareperfusion injury, cardiac remodeling and development of Heart Failure (HF). In this review we have summarized the recent studies investigating the role of TLRs in CVD and the potential for using TLRs signaling pathways as a therapeutic target in CVD.
Keywords: Cardiovascular disease, immune system, Toll-like receptors, signaling pathway, atherogenesis, stroke.
Current Pharmaceutical Design
Title:Toll-like Receptors Signaling Pathways as a Potential Therapeutic Target in Cardiovascular Disease
Volume: 24 Issue: 17
Author(s): Seyed Mostafa Parizadeh, Maryam Ghandehari, Motahareh Heydari-majd, Sima Seifi, Ramin Mardani, Seyed Mohamadreza Parizadeh, Majid Ghayour-Mobarhan, Gordon A. Ferns, Seyed Mahdi Hassanian*Amir Avan*
Affiliation:
- Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad,Iran
- Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad,Iran
Keywords: Cardiovascular disease, immune system, Toll-like receptors, signaling pathway, atherogenesis, stroke.
Abstract: Cardiovascular Disease (CVD) is one of the most important causes of morbidity and mortality, and associated with an important economic burden globally. Over the last decade, the prevalence of CVD has been rising globally, and is now associated with millions of death annually in both developed and developing countries. There is good evidence that the immune system is involved in the pathophysiology of CVD. Toll-like receptors (TLRs) and their down-stream signaling pathways play an important role in the immune system. Recent studies have suggested that the TLRs are involved in atherogenesis, including stroke, myocardial infarction, ischemiareperfusion injury, cardiac remodeling and development of Heart Failure (HF). In this review we have summarized the recent studies investigating the role of TLRs in CVD and the potential for using TLRs signaling pathways as a therapeutic target in CVD.
Export Options
About this article
Cite this article as:
Parizadeh Mostafa Seyed , Ghandehari Maryam , Heydari-majd Motahareh , Seifi Sima , Mardani Ramin , Parizadeh Mohamadreza Seyed , Ghayour-Mobarhan Majid , Ferns A. Gordon , Hassanian Mahdi Seyed *, Avan Amir *, Toll-like Receptors Signaling Pathways as a Potential Therapeutic Target in Cardiovascular Disease, Current Pharmaceutical Design 2018; 24 (17) . https://dx.doi.org/10.2174/1381612824666180614090224
DOI https://dx.doi.org/10.2174/1381612824666180614090224 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetic Cardiomyopathy and its Prevention by Metallothionein: Experimental Evidence, Possible Mechanisms and Clinical Implications
Current Medicinal Chemistry The Trigeminocardiac Reflex as Oxygen Conserving Reflex in Humans: Its Ischemic Tolerance Potential
Vascular Disease Prevention (Discontinued) Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design Early Intervention in Psychosis: Rationale, Results and Implications for Treatment of Adolescents at Risk
Adolescent Psychiatry Endothelin Receptor Antagonists: Another Potential Alternative for Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders p35 Deficiency Accelerates HMGB-1-mediated Neuronal Death in the Early Stages of an Alzheimer's disease Mouse Model
Current Alzheimer Research Induced Pluripotent Stem Cells as a Model for Accelerated Patient- and Disease-specific Drug Discovery
Current Medicinal Chemistry Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in Experimental Myocarditis
Current Pharmaceutical Design Identification of Candidate Biomarkers of Acute Aortic Dissection
Recent Patents on DNA & Gene Sequences Takotsubo Syndrome: Clinical Manifestations, Etiology and Pathogenesis
Current Cardiology Reviews Preparation, Characterization, and In Vitro Release of Vinorelbine Tartrate (VLBT)- Loaded Folate-conjugated Recombination Human Serum Albumin (rHSA) Nanoparticles with Different Degree of Cross-linking
Current Nanoscience Therapeutic Drugs that Slow the Heart Rate of Early Rat Embryos. Is there a Risk for the Human?
Current Pharmaceutical Design Non-glycemic Adverse Effects of Insulin
Current Diabetes Reviews Cardiovascular Risk Factors in Chronic Inflammatory Rheumatic Diseases: Modern Assessment and Diagnosis
Current Vascular Pharmacology Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Drugs for the Treatment of Hypercholesterolemia and their Benefits Beyond Cholesterol Lowering to Prevent Vascular Disease
Vascular Disease Prevention (Discontinued) Deciphering the Physiology Underlying the Rapid Clinical Effects of Perispinal Etanercept in Alzheimers Disease
Current Alzheimer Research XMT-1001, A Novel Biodegradable Polyacetal Polymer Conjugate of Camptothecin in Clinical Development
Current Bioactive Compounds Novel Molecular Targets in the Treatment of Cardiac Hypertrophy
Recent Patents on Cardiovascular Drug Discovery